According to GeekWire, Seattle startup Accipiter Bio just emerged from stealth with $12.7 million in seed funding and major pharmaceutical partnerships with Pfizer and Kite Pharma. The company spun out from University of Washington’s Institute for Protein Design, which is led by 2024 Nobel Chemistry Prize winner David Baker. They’re using AI tools developed in that lab to engineer completely new proteins that can bind multiple cellular targets simultaneously. The Pfizer deal alone could be worth over $330 million in milestone payments and royalties, while the Kite Pharma agreement gives them option rights on molecules developed for cell therapies. Accipiter Bio already has four internal drug programs, with two preparing for FDA discussions about human testing.
The multi-target revolution
Here’s what makes this approach genuinely interesting. Drug combinations often work better than single therapies, but coordinating them is incredibly difficult. You’re basically trying to get two separate drugs to arrive at the same place at the same time and work together perfectly. Accipiter’s solution? Design single proteins that naturally hit multiple targets from the start.
Think about cancer treatment. Sometimes you need to trigger several cellular functions simultaneously to create what CEO Matthew Bick calls a “multiplicative” effect rather than just additive. But the regulatory and development advantages might be even more compelling. When you combine two separate drugs, each needs its own Phase 1 safety trial plus another trial testing them together. A single multi-functional protein? Just one Phase 1 trial. That’s potentially years and millions of dollars saved.
Nobel pedigree meets hard lessons
The team’s background is both impressive and battle-tested. All three co-founders previously worked at Neoleukin Therapeutics, another protein design company that spun out from the same UW lab. Neoleukin’s lead drug candidate ultimately underperformed in Phase 1 trials, leading to layoffs and a merger.
But here’s the thing – that experience might be their secret weapon. Bick says they learned crucial lessons about running multiple programs simultaneously and preventing immunogenicity (unwanted immune responses to engineered proteins). They were part of the team that took “the first fully de novo protein into patients.” That’s valuable scar tissue you can’t get from success alone.
Where this could lead
We’re seeing something fundamental shift in biotech. As Flying Fish Partners’ Heather Gorham noted, computation isn’t just speeding up biology anymore – it’s expanding what’s biologically possible. The ability to design proteins from scratch rather than tweaking existing ones opens up entirely new therapeutic modalities.
Accipiter’s early focus on cancers and irritable bowel syndrome makes sense – these are complex diseases where multi-target approaches could really shine. But the platform’s potential extends much further. If they can reliably design proteins that hit multiple targets with precision, we might be looking at a new generation of smarter, more efficient biologics.
The fact that pharmaceutical giants like Pfizer are already betting big suggests this isn’t just academic curiosity. They’re putting real money behind the idea that AI-designed multi-target proteins could solve “previously unattainable” therapeutic problems. It’s still early days, and drug development remains brutally difficult, but the convergence of Nobel-winning science, hard-won experience, and serious industry backing makes this one to watch. Check out their approach at accipiterbio.com.
I could not resist commenting. Perfectly written!
Wonderful beat ! I wish to apprentice even as you amend your web site, how can i subscribe for a weblog web site?
The account helped me a applicable deal. I have been tiny bit acquainted
of this your broadcast offered vibrant transparent idea
Hello, I enjoy reading through your post. I like to write a little comment
to support you.
Hi there it’s me, I am also visiting this web page daily, this web site is actually nice and the people are genuinely sharing nice thoughts.
magnificent issues altogether, you simply gained a new reader.
What would you suggest in regards to your put up that
you just made a few days in the past? Any positive?
Undeniably believe that which you said. Your favorite justification appeared to be on the
internet the simplest thing to be aware of. I say to you, I
definitely get annoyed while people consider worries that they plainly don’t know
about. You managed to hit the nail upon the top
and defined out the whole thing without having side effect ,
people could take a signal. Will likely be back to get more.
Thanks
I’ve been surfing online more than 4 hours today, yet I never found any
interesting article like yours. It’s pretty worth enough for me.
Personally, if all website owners and bloggers made good content as you
did, the internet will be a lot more useful than ever before.
Excellent article. I certainly love this website. Keep writing!
My spouse and I absolutely love your blog and find almost all of your post’s to be just what I’m looking for.
Would you offer guest writers to write content available for you?
I wouldn’t mind publishing a post or elaborating on most of
the subjects you write in relation to here. Again, awesome weblog!
Hi to all, since I am genuinely keen of reading this blog’s post to be updated on a regular basis.
It contains nice material.
you’re really a just right webmaster. The web site loading
velocity is amazing. It kind of feels that you are doing any distinctive
trick. Also, The contents are masterwork. you’ve performed
a magnificent process on this subject!
What’s Taking place i’m new to this, I stumbled upon this I’ve discovered It
positively useful and it has helped me out loads. I am hoping to give a
contribution & aid different customers like its aided me.
Good job.
We’re a gaggle of volunteers and starting a new scheme
in our community. Your site provided us with valuable information to work on.
You’ve performed a formidable job and our whole community will probably be
grateful to you.
Thank you for your sharing. I am worried that I lack creative ideas. It is your article that makes me full of hope. Thank you. But, I have a question, can you help me?
Thank you for your sharing. I am worried that I lack creative ideas. It is your article that makes me full of hope. Thank you. But, I have a question, can you help me?
Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me.